

European Perspective on Scope of Practice of Dermatology



EBERHARD KARLS
UNIVERSITÄT
TÜBINGEN



Martin Röcken



Dept. of Dermatology, University Tübingen
German Society of Dermatology





Zurich
Switzerland



Tübingen
Germany



Paris
France



European Perspective on Scope of Practice of Dermatology

- 70^{ies} & 80^{ies} defining the scope of Dermatology
 - Scope of Dermatology large – in terms of medical and surgical Dermatology
 - Dermatohistopathology
- 80^{ies} & 90^{ies} focus on pathogenesis – Genetics, molecular and functional level – immune dermatology, microbiology

Volume 138, Number 5S, Supplement 1, May 2018


www.jidonline.org

Supplement to the Journal of Investigative Dermatology

One way further developed was ...

JID

JOURNAL OF INVESTIGATIVE DERMATOLOGY



Development of Academic Dermatology in Europe

Focus on severe diseases

Focus on entire spectrum in it's
depth and breadth

Academic Dermatology in Europe

- Fitzpatrick et al., Rook et al. -

Allergies

Autoinflammation

Autoimmune diseases

Genetic diseases

Infections – viral – bacterial – mycotic

Vascular diseases

Medical oncology and cancer therapy

Surgical oncology and cancer therapy

Academic Dermatology in Europe

Focus on severe diseases

Focus on entire spectrum in it's
depth and breadth

From clinical definition & pathogenesis
to
development of novel therapies

Inhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous Immunoglobulin


Science

Isabelle Viard, Philippe Wehrli,* Roberto Bullani,*
Pascal Schneider, Nils Holler, Denis Salomon, Thomas Hunziker,
Jean-Hilaire Saurat, Jürg Tschopp, Lars E. French†



Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

Christopher E.M. Griffiths, M.D., Bruce E. Strober, M.D., Ph.D.,
Peter van de Kerkhof, M.D., Vincent Ho, M.D., Roseanne Fidelus-Gort, Ph.D.,
Newman Yeilding, M.D., Cynthia Guzzo, M.D.,
Bei Zhou, Ph.D., Shu Li, M.S., Lisa T. Dooley, Dr.P.H.
and Alan Menter, M.D., for the ACCEPT



Academic Dermatology in Europe

Allergies

Autoinflammation

Autoimmune diseases

Genetic diseases

Infections – viral – bacterial – mycotic

Vascular diseases


Medical oncology and cancer therapy

Surgical oncology and cancer therapy

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Caroline Robert, M.D., Ph.D., Luc Thomas, M.D., Ph.D.,
 Igor Bondarenko, M.D., Ph.D., Steven O'Day, M.D., Jeffrey Weber M.D., Ph.D.,
 Claus Garbe, M.D., Celeste Lebbe, M.D., Ph.D., Jean-François Baurain, M.D., Ph.D.,
 Alessandro Testori, M.D., Jean-Jacques Grob, M.D., Neville Davidson, M.D.,
 Jon Richards, M.D., Ph.D., Michele Maio, M.D., Ph.D., Axel Hauschild, M.D.,

A



No. at Risk


Ipilimumab-dacarbazine	250	230	199	181	157	131	114	104	91	85	79	74	68	61	59	56	56	52	41	31	17	10	4	2	0
Placebo-dacarbazine	252	229	190	160	136	116	89	78	72	64	56	47	44	42	42	37	34	31	26	19	11	7	5	3	0

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

Caroline Robert, M.D., Ph.D., Georgina V. Long, M.D., Ph.D., Benjamin Brady, M.D.,
 Caroline Dutriaux, M.D., Michele Maio, M.D., Laurent Mortier, M.D.,
 Jessica C. Hassel, M.D., Piotr Rutkowski, M.D., Ph.D., Catriona McNeil, M.D., Ph.D.,
 Ewa Kalinka-Warzocha, M.D., Ph.D., Kerry J. Savage, M.D.,
 Micaela M. Hernberg, M.D., Ph.D., Celeste Lebbé, M.D., Ph.D.,
 Julie Charles, M.D., Ph.D., Catalin Mihalciou, M.D., Vanna Chiarion-Sileni, M.D.,
 Cornelia Mauch, M.D., Ph.D., Francesco Cognetti, M.D., Ana Arance, M.D., Ph.D.,
 Henrik Schmidt, M.D., D.M.Sc., Dirk Schadendorf, M.D., Helen Gogas, M.D.,
 Lotta Lundgren-Eriksson, M.D., Christine Horak, Ph.D., Brian Sharkey, Ph.D.,
 Ian M. Waxman, M.D., Victoria Atkinson, M.D., and Paolo A. Ascierto, M.D.





B Progression-free Survival



No. at Risk

	210	116	82	57	12	1	0
Nivolumab	210	116	82	57	12	1	0
Dacarbazine	208	74	28	12	0	0	0

Treatment of Metastatic Melanoma




Diagnosis & Treatment of Side Effects



Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

Antoni Ribas, [Reinhard Dummer](#), Igor Puzanov, Ari VanderWalde, Robert H.I. Andtbacka, Olivier Michielin, Anthony J. Olszanski, Josep Malvehy, Jonathan Cebon, Eugenio Fernandez, John M. Kirkwood, Thomas F. Gajewski, Lisa Chen, Kevin S. Gorski, Abraham A. Anderson, Scott J. Diede, Michael E. Lassman, Jennifer Gansert, F. Stephen Hodi, Georgina V. Long

Cell



Academic Dermatology in Europe

Allergies

Autoinflammation

Autoimmune diseases

Genetic diseases

Infections – viral – bacterial – mycotic

Vascular diseases

Medical oncology and cancer therapy

Surgical oncology and cancer therapy

Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study



Kay D Brantsch, Christoph Meisner, Birgitt Schönfisch, Birgit Trilling, Jörg Wehner-Caroli, Martin Röcken, Helmut Breuninger

Summary


Background Cutaneous squamous-cell carcinomas (SCC) are among the most common cancers capable of metastasis. Current Tumour Node Metastasis (TNM) staging includes horizontal tumour size, involvement of extradermal structures, and degree of differentiation. The aim of this study was to prospectively analyse the key factors predicting metastasis and local recurrence in cutaneous SCC.

Lancet Oncol 2008; 9: 713-20

Published Online

July 9, 2008

DOI:10.1016/S1470-2045(08)70178-5



Academic Dermatology in Europe

Allergies

Autoinflammation

Autoimmune diseases

Genetic diseases

Infections – viral – bacterial – mycotic


Vascular diseases

Medical oncology and cancer therapy

Surgical oncology and cancer therapy

Articles

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

Professor Pascal Joly MD ^a , Maud Maho-Vaillant PhD ^a, Prof Catherine Prost-Squarcioni MD ^b, Vivien Hebert MD ^a, Estelle Houivet MS ^c, Sébastien Calbo PhD ^a, Frédérique Caillot PhD ^a, Marie Laure Golinski PhD ^a, Prof Bruno Labeille MD ^d, Catherine Picard-Dahan MD ^e, Prof Carle Paul MD ^f, Prof Marie-Aleth Richard MD ^g, Prof Jean David Bouaziz MD ^h, Sophie Duvert-Lehembre MD ^a, Prof Philippe Bernard MD ⁱ, Prof Frederic Caux MD ^b,



Academic Dermatology in Europe

Allergies

Autoinflammation

Autoimmune diseases

Genetic diseases

Infections – viral – bacterial – mycotic

Vascular diseases



Medical oncology and cancer therapy

Surgical oncology and cancer therapy

BRIEF REPORT

Integrin α_3 Mutations with Kidney, Lung, and Skin Disease

Cristina Has, M.D., Giuseppina Spartà, M.D., Dimitra Kiritsi, M.D.,
Lisa Weibel, M.D., Alexander Moeller, M.D., Virginia Vega-Warner, Ph.D.,
Aoife Waters, M.D., Yinghong He, M.D., Yair Anikster, M.D., Ph.D.,
Philipp Esser, Ph.D., Beate K. Straub, M.D., Ingrid Hausser, Ph.D.,
Detlef Bockenhauer, M.D., Ph.D., Benjamin Dekel M.D., Ph.D.,
Friedhelm Hildebrandt, M.D., Leena Bruckner-Tuderman, M.D.,




Regeneration of the entire human epidermis using transgenic stem cells

Tobias Hirsch^{1*}, Tobias Rothoef^{2*}, Norbert Teig^{2*}, Johann W. Bauer^{3*}, Graziella Pellegrini^{4,5*}, Laura De Rosa^{5*}, Davide Scaglione⁶, Julia Reichelt³, Alfred Klausegger³, Daniela Kneisz³, Oriana Romano⁷, Alessia Secone Seconetti⁵, Roberta Contin⁵, Elena Enzo⁵, Irena Jurman⁸, Sonia Carulli⁹, Frank Jacobsen¹, Thomas Luecke¹⁰, Marcus Lehnhardt¹, Meike Fischer², Maximilian Kueckelhaus¹, Daniela Quaglino⁷, Michele Morgante⁸, Silvio Bicciato⁷, Sergio Bondanza⁹ & Michele De Luca⁵



European Perspective on Scope of Practice of Dermatology

Size of Dermatology Departments in Europe



European Perspective on Scope of Practice of Dermatology

Focus on severe diseases
Focus on entire spectrum in it's
depth and breadth

Profound knowledge in
general medicine
internal medicine
immunology

European Perspective on Scope of Practice of Dermatology

Where dermatology commits seriously to
focus on severe diseases,
the entire spectrum in it's depth and breadth
PATIENTS have a bright future

where not
PATIENTS have a poor future

Thank you
for your attention

